<DOC>
	<DOCNO>NCT01486459</DOCNO>
	<brief_summary>Small cell lung cancer aggressive neuroendocrine tumour often present extensive ( metastatic ) disease . Chemotherapy mainstay treatment , radiotherapy primary tumour . It part care also offer Prophylactic Cranial Irradiation ( PCI ) order prevent spread cancer brain . Cognitive impairment result cranial irradiation . Lithium think neuroprotective . It hypothesize lithium administration PCI safe , tolerable feasible , studied prevent ameliorate ensue cognitive impairment .</brief_summary>
	<brief_title>A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer</brief_title>
	<detailed_description>Small cell lung cancer ( SCLC ) aggressive neuroendocrine tumour often present extensive ( metastatic ) disease . [ 1 ] It frequently micrometastatic disease presentation . Chemotherapy mainstay treatment radiotherapy primary tumour . It part care offer Prophylactic Cranial Irradiation ( PCI ) 25 Gy 10 fraction dependent extent response primary tumour patient 's performance status . PCI routine care limited stage patient show response consider select patient limited stage disease show good response.Somnolence syndrome common intermediate side effect cranial radiotherapy occur six week treatment manifest lethargy , increase sleepiness poor attention subtle memory change alter temperament [ 2 ] . The use cranial irradiation link neurocognitive complication long term memory , mood concentration issue [ 3 ] . Decline attention , executive function , motor , language general intellectual skill report . There suggestion rapid progression dementing illness patient receive cranial irradiation although number long term survivor limit [ 3 ] . Radiation mediate neurocognitive effect affect glial cell , neural stem progenitor cell [ 4 , 5 ] vascular structure [ 3 , 6 ] . Cranial irradiation deliver mice show reduce neural proliferation translate long term reduction neurogenesis [ 7 , 8 ] . Lithium confers neuroprotection associate less cognitive loss various brain injury model include cranial irradiation [ 9 , 10 ] . In addition , neural stem/progenitor cell positively respond Lithium treatment basal condition [ 11 , 12 ] . In human , 4 week Lithium increase brain grey matter content [ 13 ] hippocampal volume [ 14 ] evidence MRI scan . Lithium find protect irradiate hippocampal neuron mice apoptosis result good performance reflect learn memory function [ 10 ] . Lithium known reduce oxidative stress , specifically via glutathione system . Lithium standard part management moderate severe bipolar disorder schizoaffective disorder toxicity profile well understood [ 15 , 16 ] . In bipolar disorder , lithium show prevent loss cortical grey matter occur part neuroprogressive cascade see disorder [ 17 ] . There limited prospective clinical data regard use lithium neuroprotectant . A large Danish observational cohort study , demonstrate use lithium ( mood disorder , display increase risk dementia ) associate reduction rate dementia level general population [ 18 ] . A follow study group show similar finding [ 19 ] . A metaanalysis lithium cognitive performance demonstrate minor negative effect cognition [ 20 ] . There one early phase study use lithium neuroprotective agent present abstract form 2007 American Society Therapeutic Radiology Oncology ( ASTRO ) [ 21 ] updated 2008 annual meeting Society NeuroOncology ( SNO ) [ 22 ] . Long term lithium treatment also show promise amnestic mild cognitive impairment study randomize 45 participant receive lithium ( 0.25-0.5 mmol/l ) ( n = 24 ) placebo ( n = 21 ) 12 month , doubleblind trial [ 23 ] . Lithium treatment associate significant decrease CSF concentration Ptau ( P =0.03 ) good performance cognitive subscale Alzheimer 's Disease Assessment Scale attention task . The data support notion lithium disease modify property potential clinical implication prevention Alzheimer 's disease . [ 23 ] References : 1 . Turrisi AT , 3rd , Kim K , Blum R et al . Twice daily compare daily thoracic radiotherapy limit small cell lung cancer treat concurrently cisplatin etoposide . N England J Med 1999 ; 340 : 265271 . 2 . Kelsey CR , Marks LB . Somnolence syndrome focal radiation therapy pineal region : case report review literature . J Neurooncol 2006 ; 78 : 153156 . 3 . Armstrong CL , Gyato K , Awadalla AW et al . A critical review clinical effect therapeutic irradiation damage brain : root controversy . Neurophysiol Rev 2004 ; 14 : 6586 . 4 . Monje ML , Vogel H , Masek M et al . Impaired human hippocampal neurogenesis treatment central nevrous system malignancy . Ann Neurol . 2007 ; 62 , 515520 . 5 . Monje ML , Palmer T. Radiation injury neurogenesis . Curr Opin Neurol . 2003 ; 129134 . 6 . Perry A , Schmidt RE . Cancer therapy associate CNS neuropathology : update review literature . Acta Neuropathol 2006 ; 111 : 197212 . 7 . Rola R , Raber J , Rizk A et al . Radiation induce impairment hippocampal neurogenesis associate cognitive deficit young mouse . Exp Neurol 2004 ; 188 : 316330 . 8 . Vorhees CV , Williams MT . Morris water maze procedure assess spatial related form learn memory . Nat Protoc 2006 ; 1 : 848858 . 9 . Rowe MK , Chuang DM . Lithium neuroprotection : molecular mechanism clinical implication . Expert Rev Mol . Med . 2004 ; 6 : 118 . 10 . Yazlovitskaya EM , Edwards E , Thotala D et al . Lithium treatment prevents neurocognitive deficit result cranial irradiation . Cancer Res 2006 ; 66 : 1117911186 . 11 . Chen G , Rajokowska G , Du F et al . Enhancement hippocampal neurogenesis lithium . J. Neurochem . 2000 ; 75 : 17291734 . 12 . Yan XB , Hou HL , Wu LM et al . Lithium regulate hippocampal neurogenesis ERK pathway facilitate recovery spatial learn memory rat transient global cerebral ischemia . Neuropharmacology 2007 ; 53 : 487495 . 13 . Moore GJ , Bebchuk JM , WIlds IB et al . Lithium induce increase human brain grey matter . Lancet 2000 ; 356:12411242 . 14 . Foland LC , Altshuler LL , Sugar CA et al . Increased volume amygdala hippocampus bipolar patient treat lithium . Neuroreport 2008 ; 19:221224 . 15 . Dowdan J . Therapeutic Guidelines : Psychotropic . ( Version 5 ) . Melbourne : 2003 . 16 . Foutoulakis KN , Vieta E , SanchezMoreno J et al . Treatment guideline bipolar disorder : critical review . J Affect Disord 2005 ; 86:110 . 17 . Berk M , Kapczinski F , Andreazza AC et al . Pathways underlie neuroprogression bipolar disorder : focus inflammation , oxidative stress neurotrophic factor . Neurosci Biobehav Rev 2011 ; 35:804817 . 18 . Kessing LV , SOndergard L , Forman JL , Andersen PK . Lithium treatment risk dimential . Arch Gen Psychiatry 2008 ; 65 : 13311335 . 19 . Kessing LV , Forman JL , Andersen PK . Does lithium protect dementia ? Bipolar Disord 2010 ; 12 : 8794 . 20 . Wingo AP , Wingo TS , Harvey PD , Baldessarini RJ . Effects lithium cognitive performance : metaanalysis . J. Clin Psychiatry 2009 ; 70 : 15881597 . 21 . Yang ES , Lu B , Hallahan DE . Lithium mediate neuroprotection cranial irradiation : A phase 1 trial . In ASTRO ( American SOciety Therapeutic Radiology Oncology ) 49th Annual Conference . Los Angeles CA : 2007 [ 22 ] Xia F , Yang E , Hallahan D , Lu B. Lithium mediate neuroprotection cranial irradiation : phase I trial . Neurooncology 2008 ; 10 : 887887 . [ 23 ] Forlenza OV , Diniz BS , Radanovic M et al . Disease modify property long term lithium treatment amnestic mild cognitive impairment : randomize controlled trial . The British Journal Psychiatry : The Journal Mental Science 2011 ; 198 : 351356 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>Histologically cytologically confirm high grade small cell neuroendocrine carcinoma . Patients either : Limited stage disease CR PR OR Extensive stage disease CR good PR Patients must discontinue chemotherapy least 3 week prior randomisation . Prior radiation therapy chest allow must complete least 3 week prior randomisation . ECOG Performance Status 0 2 . Adequate bone marrow , liver , renal function assess follow : Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin ≤ 2.0 time upper limit normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x upper limit normal ( ≤ 5x ULN patient liver involvement ) International Normalized Ratio Prothrombin Time ( PTINR ) ≤ 1.5 activate partial prothrombin time ( aPTT ) within 5 % normal limit patient NOT anticoagulation . Estimated Glomerular Filtration Rate ( eGRF ) &gt; 50 ml/min . Male female age &gt; 18 year Patients must able willing sign write informed consent . A sign informed consent must appropriately obtain prior study specific procedure . Patients must able swallow retain oral medication . Women childbearing potential must negative serum pregnancy test perform within 7 day prior randomisation must agree use adequate contraception prior randomisation duration study participation . Life expectancy le 3 month . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result . Severe cardiac renal disease . Frank hypothyroidism . Hyponatraemia . Known suspect allergy lithium . Women pregnant breastfeeding . Inability comply protocol /or willing available followup assessment . Significant psychiatric neurologic illness ( prior know psych/cognitive/CNS pathology eg CVA ; know prior brain metastasis Current lithium therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>